Humacyte FY2025 net loss narrows to $40.8 million; revenue rises to $2.0 million

Reuters03-27
Humacyte FY2025 net loss narrows to $40.8 million; revenue rises to $2.0 million
  • Humacyte published a fourth-quarter and full-year 2025 earnings press release, reporting total revenue of USD 467,000 for Q4 and USD 2.04 million for FY 2025.
  • Product revenue was USD 439,000 in Q4 on 25 Symvess units and USD 1.39 million in FY 2025 on 61 units, while contract revenue was USD 28,000 in Q4 and USD 649,000 in FY 2025.
  • Net loss was USD 24.8 million in Q4 and USD 40.8 million in FY 2025, with FY R&D expense down 21.8% to USD 69.3 million due to a shift from development to commercial operations after Symvess’ FDA approval and lower clinical study costs.
  • Cash and cash equivalents were USD 50.5 million as of Dec. 31, 2025, and the company said it raised USD 18.4 million in net proceeds in a registered direct offering and USD 4.6 million via its at-the-market facility after year-end.
  • Business updates included 27 Value Analysis Committee approvals for Symvess with 43 additional reviews underway, a minimum Symvess purchase commitment of USD 1.48 million for a clinical evaluation program in Saudi Arabia, and an expected top-line interim readout by early June 2026 from the V012 Phase 3 hemodialysis access study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679535) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment